Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter?
Abstract There is a vast disagreement in relation to the possible beneficial effects of omega-3 polyunsaturated fatty acids (omega-3 PUFA) supplementation in patients with diabetes and cardiovascular disease. The conflicting results between the various original studies and meta-analyses could be par...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-08-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12933-018-0766-0 |
| _version_ | 1817997744251338752 |
|---|---|
| author | Alexander Tenenbaum Enrique Z. Fisman |
| author_facet | Alexander Tenenbaum Enrique Z. Fisman |
| author_sort | Alexander Tenenbaum |
| collection | DOAJ |
| description | Abstract There is a vast disagreement in relation to the possible beneficial effects of omega-3 polyunsaturated fatty acids (omega-3 PUFA) supplementation in patients with diabetes and cardiovascular disease. The conflicting results between the various original studies and meta-analyses could be partially explained as a result of variable supplementation dosage and duration, either of which may modify the effects of omega-3 PUFA on cardio-metabolic biomarkers. Meta-analyses are limited usually by the inability to draw inferences regarding dosage, duration and the interaction of dosage and duration of omega-3 PUFA intake. Even so, almost all endpoints in the so-called “negative” meta-analyses leaned toward a trend for benefit with a near 10% reduction in cardiovascular outcomes and a borderline statistical significance. Many trials included in these meta-analyses tested an insufficient daily dose of omega-3 PUFA of less than 1000 mg. Probably, the consistent cardiovascular effects of omega-3 PUFA supplements could be expected only with daily doses above 2000 mg. |
| first_indexed | 2024-04-14T02:42:52Z |
| format | Article |
| id | doaj.art-d886c246ce4140b58a8a0996a7555665 |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-04-14T02:42:52Z |
| publishDate | 2018-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-d886c246ce4140b58a8a0996a75556652022-12-22T02:16:48ZengBMCCardiovascular Diabetology1475-28402018-08-011711310.1186/s12933-018-0766-0Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter?Alexander Tenenbaum0Enrique Z. Fisman1Sackler Faculty of Medicine, Tel Aviv UniversitySackler Faculty of Medicine, Tel Aviv UniversityAbstract There is a vast disagreement in relation to the possible beneficial effects of omega-3 polyunsaturated fatty acids (omega-3 PUFA) supplementation in patients with diabetes and cardiovascular disease. The conflicting results between the various original studies and meta-analyses could be partially explained as a result of variable supplementation dosage and duration, either of which may modify the effects of omega-3 PUFA on cardio-metabolic biomarkers. Meta-analyses are limited usually by the inability to draw inferences regarding dosage, duration and the interaction of dosage and duration of omega-3 PUFA intake. Even so, almost all endpoints in the so-called “negative” meta-analyses leaned toward a trend for benefit with a near 10% reduction in cardiovascular outcomes and a borderline statistical significance. Many trials included in these meta-analyses tested an insufficient daily dose of omega-3 PUFA of less than 1000 mg. Probably, the consistent cardiovascular effects of omega-3 PUFA supplements could be expected only with daily doses above 2000 mg.http://link.springer.com/article/10.1186/s12933-018-0766-0AtherogenesisCardiovascular risk reductionCoronary artery diseaseDyslipidemiaHypertriglyceridemiaOmega 3 supplements |
| spellingShingle | Alexander Tenenbaum Enrique Z. Fisman Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter? Cardiovascular Diabetology Atherogenesis Cardiovascular risk reduction Coronary artery disease Dyslipidemia Hypertriglyceridemia Omega 3 supplements |
| title | Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter? |
| title_full | Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter? |
| title_fullStr | Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter? |
| title_full_unstemmed | Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter? |
| title_short | Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter? |
| title_sort | omega 3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk does dose really matter |
| topic | Atherogenesis Cardiovascular risk reduction Coronary artery disease Dyslipidemia Hypertriglyceridemia Omega 3 supplements |
| url | http://link.springer.com/article/10.1186/s12933-018-0766-0 |
| work_keys_str_mv | AT alexandertenenbaum omega3polyunsaturatedfattyacidssupplementationinpatientswithdiabetesandcardiovasculardiseaseriskdoesdosereallymatter AT enriquezfisman omega3polyunsaturatedfattyacidssupplementationinpatientswithdiabetesandcardiovasculardiseaseriskdoesdosereallymatter |